Satellos Bioscience Inc. (MSLE)

Satellos Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	19.3	42.23	16.16
Short-Term Investments	15.31	8.93	12.84
Cash & Cash Equivalents	34.61	51.17	29
Cash Growth	-	76.44%	-
Other Current Assets	2.88	2.31	0.54
Total Current Assets	37.5	53.48	29.54
Property, Plant & Equipment	-	0	0.01
Long-Term Investments	-	0	0.03
Goodwill and Intangibles	-	0	2.87
Other Long-Term Assets	-	0	-0
Total Long-Term Assets	-	0	2.91
Total Assets	-	53.48	32.45
Accounts Payable	-	3.78	2.65
Other Current Liabilities	3.5	0	0
Total Current Liabilities	3.5	3.78	2.65
Total Liabilities	-	3.78	2.65
Retained Earnings	-	-55.38	-34.79
Comprehensive Income	-	-0.16	-0.01
Shareholders' Equity	34	49.71	29.79
Net Cash (Debt)	34.61	51.17	29
Net Cash (Debt) Growth	-	76.44%	-
Working Capital	33.99	49.7	26.88

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).